Tired of waiting and fretting over the impending release of the Lo/Alter PNAS paper? Want a nice distraction with good karmic overtones? Of course, after tons of medical expenses and inability to work consistently, the pool of CFS patients is not teeming with well-heeled investors. So this is not for us. But, even though they were probably not motivated by altruistic intent, the WSJ and business world that supports them has been invaluable in providing in depth coverage of the XMRV story and the embargoed Lo/Alter paper. The CFS community owes them a karmic debt. We can repay part of that by doing the research into which pharmaceutical and biotech companies, or any other business model for that matter, stands to profit in the case that XMRV/CFS/ME microbialists get a home run or even a grand slam with the Lo/Alter paper. Hillary Johnson has already long ago made the association with CFS and the profits of UNUM, a large disability insurer that has a history of denying claims from insured with CFS/ME. That stock would probably go down. http://www.wikinvest.com/stock/Unum_Group_(UNM) Which pharma controlling anti-retrovirals would be positively affected? Can you think of a creative scenario for profit? Diagnostic tests to protect the blood supply? What companies at we looking at?